NuVasive, Inc.(NUVA) Stock Research - Grey Stern Research

NuVasive, Inc. (NUVA) Stock Analysis

$39.75 (-2.24%)

NUVA Financial Performance


Use the table below to view NuVasive, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2023

Metric Value Ranking among Peers
Price $39.75 -
52 Week Low $35.17 -
52 Week High $49.53 -
Market Cap $2.1 Billion 7/15
Gross Margin 72% 6/15
Profit Margin 2% 6/15
EBITDA margin 19% 3/15
Q2 - 2023 Revenue $317.8 Million 5/15
Q2 - 2023 Earnings $7.4 Million 6/15
Q2 - 2023 Free Cash Flow -$495,000 Million 9/15
Trailing 4 Quarters Revenue $1.2 Billion 6/15
Trailing 4 Quarters Earnings $28.5 Million 5/15
Quarterly Earnings Growth 925% 1/15
Annual Earnings Growth -50% 13/15
Quarterly Revenue Growth 2% 12/15
Annual Revenue Growth 4% 10/15
Cash On Hand $80.7 Million 7/15
Short Term Debt $360.8 Million 1/15
Long Term Debt $545.4 Million 6/15

NuVasive, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare NuVasive, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 73.28 3/15
PS 1.70 11/15
PB 2.34 9/15
PC 25.83 6/15
Liabilities to Equity 1.34 3/15
ROA 0.01 5/15
ROE 0.03 5/15
Current Ratio 1.75 13/15
Quick Ratio 0.07 12/15
Long Term Debt to Equity 0.61 6/15
Debt to Equity 1.02 2/15
Burn Rate 0.77 13/15
Cash to Cap 0.04 8/15
CCR -0.07 14/15
EV to EBITDA 47.54 2/15
EV to Revenue 2.37 10/15

Company Details

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

CEO: Mr. J. Christopher Barry

Website: https://www.nuvasive.com

Address: 7475 Lusk Blvd San Diego, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Medical Devices

NuVasive, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to NuVasive, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Glaukos Corporation GKOS $8.3 Billion
LivaNova PLC LIVN $2.6 Billion
Masimo Corporation MASI $9.2 Billion
Bruker Corporation BRKR $8.7 Billion
Nevro Corp. NVRO $158.9 Million
Integer Holdings Corporation ITGR $4.7 Billion
CONMED Corporation CNMD $2.1 Billion
Heska Corporation HSKA $1.3 Billion
Orthofix Medical Inc. OFIX $685.6 Million
OrthoPediatrics Corp. KIDS $631.6 Million
Avanos Medical, Inc. AVNS $724.7 Million
SI-BONE, Inc. SIBN $690.7 Million
Pulmonx Corporation LUNG $265.4 Million
Paragon 28, Inc. FNA $858.1 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
NUVA Income Statements
Quarter Year Revenue Earnings
Q2 2023 $ 317.8 Million $7.4 Million
Q1 2023 $ 307.7 Million -$1.0 Million
Q4 2022 $ 305.4 Million $24.1 Million
Q3 2022 $ 295.3 Million -$2.0 Million
Q2 2022 $ 310.5 Million -$893,000
Q1 2022 $ 290.8 Million $19.2 Million
Q4 2021 $ 302.1 Million -$36.7 Million
Q3 2021 $ 270.8 Million -$21.6 Million

View All

NUVA Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2023 $80.7 Million $2.1 Billion $906.1 Million $892.5 Million
Q1 2023 $181.2 Million $2.2 Billion $1.0 Billion $873.7 Million
Q4 2022 $248.7 Million $2.2 Billion $1.0 Billion $868.9 Million
Q3 2022 $237.5 Million $2.2 Billion $1.5 Billion $832.1 Million
Q2 2022 $226.0 Million $2.2 Billion $1.5 Billion $826.6 Million
Q1 2022 $205.3 Million $2.2 Billion $1.9 Billion $811.9 Million
Q4 2021 $246.1 Million $2.2 Billion $1.0 Billion $795.2 Million
Q3 2021 $234.6 Million $2.1 Billion $1.0 Billion $824.2 Million

View All

NUVA Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2023 -$495,000 -$37.0 Million -$100.5 Million
Q1 2023 -$33.2 Million -$35.1 Million -$67.5 Million
Q4 2022 $14.5 Million -$32.3 Million $11.2 Million
Q3 2022 $15.9 Million -$38.4 Million $11.5 Million
Q2 2022 $26.0 Million -$35.5 Million $20.7 Million
Q1 2022 -$26.7 Million -$33.2 Million -$40.8 Million
Q4 2021 $11.8 Million -$25.6 Million $11.5 Million
Q3 2021 $33.2 Million -$32.1 Million $30.4 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions